Hikma Launches Triamcinolone Acetonide Injectable 40mg/mL In the U.S.Market

Hikma Pharmaceuticals PLC, a global pharmaceutical company, has introduced Triamcinolone Acetonide Injectable Suspension, USP (40mg/mL) in the U.S. market. The corticosteroid injection is used to treat a broad spectrum of conditions, including inflammatory, autoimmune, and hormonal disorders. This launch adds to Hikma’s steadily expanding range of essential injectable therapies aimed at addressing diverse medical needs.

Dr Bill Larkins, President of Injectables, commented, "We are excited to launch Triamcinolone Acetonide Injection in the US, a complex injectable suspension and the first of its kind in our portfolio. This launch demonstrates our ability to develop and manufacture complex products, and we look forward to continuing to deliver solutions that help improve patient outcomes."

Over the period, U.S. sales of Triamcinolone Acetonide Injectable Suspension, USP, 40mg/mL, were approximately $39 million in the 12 months ending February 2025.IQVIA reports.  Recently, Hikma became one of the leading sources of generic injectable drugs in the US. The company, with more than 170 injectable drugs, keeps working on introducing novel formulations and efficient dosage options for better care of its patients.